Results 111 to 120 of about 1,869 (168)

A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'". [PDF]

Dermatol Ther (Heidelb)
Augustin M, Armstrong AW, Issa NT, Petersen AS, von Eyben R, Festini T, Torres T.   +6 more
europepmc   +1 more source

Efficacy and Safety of Topical and Systemic Therapies for Atopic Dermatitis in Patients With Skin of Colour: A Systematic Review. [PDF]

Cureus
Waqas M, Sarwar I, Junejo H, Ansari Z, Marshall BA.   +4 more
europepmc   +1 more source

Bimekizumab as an Effective Treatment in Darier Disease: Clinical Outcomes of a Single-Center Retrospective Analysis of Patients Treated with Biologics. [PDF]

Dermatol Ther (Heidelb)
Ranzinger DL, Schmidle P, Seifert M, Wasserer S, Technau-Hafsi K, Has C, Eyerich K, Pilz AC.   +7 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement. [PDF]

Dermatol Ther (Heidelb)
Gargiulo L, Ibba L, Bianco M, Di Giulio S, Valenti M, Avallone G, Zussino M, Calzari P, Marzano AV, Costanzo A, Ferrucci SM, Narcisi A.   +11 more
europepmc   +1 more source

Efficacy and Safety of Lebrikizumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Lopez-Mallama OM, Sandoval-Ato R, Vega PR, Keita H, Diaz-Gonzales G, Rivera-Lozada O, Barboza JJ.   +6 more
europepmc   +1 more source

Benign familial pemphigus treated with lebrikizumab

JAAD Case Reports
Harisankeerth Mummareddy, Nagasai C. Adusumilli, Adam J. Friedman, Christina Tolete, Joseph Zahn, Leonardo Tjahjono   +5 more
openaire   +1 more source

52792 Lebrikizumab provides stable skin response with no or minimal fluctuations for up to two years in patients with atopic dermatitis

Lebrikizumab, a high-affinity IL-13 inhibitor, demonstrated safety and efficacy as monotherapy through 52 weeks of treatment in adults and adolescents (≥40 kg) with moderate-to-severe atopic dermatitis (AD) in recent phase 3 trials (ADvocate1 ...
Vestergaard, Christian, Casillas, Marta, Lio, Peter, Carrascosa, Jose M, Stein-Gold, Linda, Gallo, Gaia, Sliverberg, Jonathan, Wollenberg, Andreas, Yang, Emily, Del Rosso, James, Fan, Yuxin D   +10 more
core  

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials. [PDF]

Acta Derm Venereol
Thaçi D, Puig L, Motegi SI, Papp K, Stein Gold L, Kircik L, Sofen H, Fernández-Peñas P, Herranz P, Vestergaard C, Huang YH, Dossenbach M, Elmaraghy H, Gallo G, Rueda MJ, Casillas M, Yang C, Agell H, Falqués M, Nosbaum A.   +19 more
europepmc   +1 more source

Correction: Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice. [PDF]

Dermatol Ther (Heidelb)
Stavropoulos N, Myszkowski D, Braß D, Dervenis V, Poungoura E, Stockfleth E.   +5 more
europepmc   +1 more source

Letter to the Editor Regarding "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison". [PDF]

Dermatol Ther (Heidelb)
Chovatiya R, Seminario-Vidal L, Gallo G, Ding Y, Yang C, Akmaz B, Solé-Feu L, Rand K.   +7 more
europepmc   +1 more source